title: Protoporphyrin IX fluorescence kinetics in C6 glioblastoma cells after delta-aminolevulinic acid incubation: effect of a protoporphyrinogen oxidase inhibitor.
abstract: PpIX synthesis after incubation with delta-aminolevulinic acid (ALA) is highly variable from one cell to another within a single cell population and in human glioblastomas in vivo. To improve PpIX synthesis, we attempted to modify the PpIX synthesis pathway in a C6 glioma cell model. To perform this experiment we used confocal microspectrofluorometry to analyse the effects of a highly purified form of sulfentrazone (FP846) on the kinetics of PpIX synthesis after ALA administration to living C6 cells. Our results show that PpIX fluorescence was maximal (seven-fold higher than basal values) 3 to 4 hrs. after the beginning of incubation with ALA. FP846 depressed this increase in fluorescence nearly to basal levels not only in C6 cells but also in HT29 and HepG2 cells. Fluorescence spectra shape were not affected by FP846, except for intensity. ALA/PpIX-induced photocytoxicity was perfectly correlated with fluorescence intensity recorded in cell cytoplasm. ALA alone (100 microg/ml) did not induce a significant decrease in cell survival, but irradiation of 25 J/cm2 leading to an overall cell death of 60%. FP846 added together with ALA suppressed ALA/PpIX-induced phototoxicity. The fact that the FP846-induced decrease in PpIX synthesis was not the same in animal and plant cells suggests that the porphyrin metabolic pathway differs due to the relative amounts of substrate or the effect of inhibitor and that another chemical would be needed alone or in combination with FP846 to improve PpIX synthesis.
authors.affiliation: Département Laser, Hôpital Laënnec, Nantes, France.
authors.forename: J
authors.initials: J
authors.lastname: Carre
authors.forename: S
authors.initials: S
authors.lastname: Eleouet
authors.forename: N
authors.initials: N
authors.lastname: Rousset
authors.forename: V
authors.initials: V
authors.lastname: Vonarx
authors.forename: D
authors.initials: D
authors.lastname: Heyman
authors.forename: Y
authors.initials: Y
authors.lastname: Lajat
authors.forename: T
authors.initials: T
authors.lastname: Patrice
mesh_terms: D000622:Aminolevulinic Acid / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D004791:Enzyme Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D005453:Fluorescence; D005909:Glioblastoma; D006801:Humans; D007700:Kinetics; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D044925:Oxidoreductases Acting on CH-CH Group Donors; D017319:Photosensitizing Agents / Q000378:metabolism* / Q000494:pharmacology; D050768:Protoporphyrinogen Oxidase; D011524:Protoporphyrins / Q000378:metabolism*; D051381:Rats; D013449:Sulfonamides; D014230:Triazoles; D014407:Tumor Cells, Cultured
chemical_list: D004791:Enzyme Inhibitors; D017319:Photosensitizing Agents; D011524:Protoporphyrins; D013449:Sulfonamides; D014230:Triazoles; C475571:N-(2,4-dichloro-5-(4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl)phenyl)methanesulfonamide; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; D050768:Protoporphyrinogen Oxidase